JSE-listed pharmaceutical company Adcock Ingram expects its earnings per share (EPS) from total operations to be increase by between 14.1% and 15.7% to between R3.80 and R3.85 for the financial year ended June 30. This compares with EPS of R3.32 reported for the 2017 financial year. Headline earnings per share from total operations are, meanwhile, expected to rise by between 21.6% and 24.8% to between R3.80 and R3.90 apiece, compared with R3.12 in 2017. Adcock will release its results on or around August 29.